Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...

Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...

December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study ...

Breast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s health. In recent years, many researchers have been focused on DCIS: ductal ...

(CNN) — Danielle Fishel is sharing an update about her health. “I am officially done with radiation, which means I am officially done with what is considered active cancer treatment,” Fishel, 43, told ...

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study ...